Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo vs. KBP: How a $1.3B deal turned into an international legal fight
Clinical Data
Biotech
Ventyx's CV drug rapidly reduces cardio risk biomarker
Ventyx Biosciences’ cardiovascular disease drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week.
James Waldron
Oct 23, 2025 9:45am
Moderna scraps congenital virus program after vax fails ph. 3
Oct 22, 2025 5:15pm
Arcturus' stock halves on cystic fibrosis readout
Oct 22, 2025 1:01pm
Alector halves staff after GSK-partnered antibody fails in ph. 3
Oct 22, 2025 11:23am
Sanofi's $1.7B bet beats CSL's Zemaira in phase 2 face-off
Oct 22, 2025 10:35am
Terns mothballs obesity program after phase 2 data fall short
Oct 22, 2025 7:15am